December 29, 2023 Regulatory Kommuniké från Promore Pharma AB:s extra bolagsstämma den 29 december 2023
December 29, 2023 Regulatory Report from the Extraordinary General Meeting of Promore Pharma AB held on 29 December 2023
December 21, 2023 Regulatory Promore Pharma AB (publ) has received approval for continued trading on Nasdaq First North Growth Market and publishes company description
December 21, 2023 Regulatory Promore Pharma AB (publ) har erhållit godkännande för fortsatt handel på Nasdaq First North Growth Market och offentliggör bolagsbeskrivning
December 8, 2023 Regulatory Update on reverse acquisition – PMD completes private placement and major shareholder receives exemption from mandatory bid requirements
December 8, 2023 Regulatory Uppdatering om det omvända förvärvet – PMD slutför riktad nyemission och större aktieägare erhåller undantag från budplikt
November 29, 2023 Regulatory Correction: NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROMORE PHARMA AB (PUBL)
November 29, 2023 Regulatory Promore Pharma AB intends to carry out a reverse acquisition of PMD Device Solutions AB
November 29, 2023 Regulatory Promore Pharma AB avser att genomföra ett omvänt förvärv av PMD Device Solutions AB
October 25, 2021 Regulatory Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers
October 25, 2021 Regulatory Promore Pharma meddelar att vetenskaplig artikel publicerats om kliniska studieresultat med ropocamptide för venösa bensår
May 15, 2019 Regulatory Inbjudan till presentation av Promore Pharmas delårsrapport för det första kvartalet 2019
March 8, 2016 Regulatory Lipopeptide AB Announces a Strategic Collaboration with Pharmaresearch Products LTD
October 10, 2013 Regulatory Pergamum Announces Final Data from Phase I/II Study in Patients with Chronic Leg Ulcers
June 27, 2013 Regulatory Pergamum Reports Positive Follow-Up Data from a Phase II Clinical Trial of PXL01 for Prevention of Post-Surgical Adhesions
February 8, 2013 Regulatory Pergamum Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd.